• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Successful nintedanib desensitization: Due to two cases.

作者信息

Tepetam Fatma Merve, Özden Şeyma, Duman Dildar

机构信息

Clinic of Immunology and Allergy, Süreyyapaşa Chest Diseases and Chest Surgery Training and Research Hospital, İstanbul, Türkiye.

Clinic of Chest Diseases, Süreyyapaşa Chest Diseases and Chest Surgery Training and Research Hospital, İstanbul, Türkiye.

出版信息

Tuberk Toraks. 2023 Mar;71(1):105-106. doi: 10.5578/tt.20239912.

DOI:10.5578/tt.20239912
PMID:36912414
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10795249/
Abstract
摘要

相似文献

1
Successful nintedanib desensitization: Due to two cases.成功的尼达尼布脱敏治疗：基于两例病例。
Tuberk Toraks. 2023 Mar;71(1):105-106. doi: 10.5578/tt.20239912.
2
Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update.尼达尼布治疗特发性肺纤维化的疗效和安全性：更新。
Drugs R D. 2018 Mar;18(1):19-25. doi: 10.1007/s40268-017-0221-9.
3
Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study.尼达尼布治疗特发性肺纤维化患者的细胞外基质代谢生物标志物（INMARK 研究）：一项随机、安慰剂对照研究。
Lancet Respir Med. 2019 Sep;7(9):771-779. doi: 10.1016/S2213-2600(19)30255-3. Epub 2019 Jul 17.
4
Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON.尼达尼布治疗特发性肺纤维化患者的长期安全性和耐受性：开放标签扩展研究 INPULSIS-ON 的结果。
Lancet Respir Med. 2019 Jan;7(1):60-68. doi: 10.1016/S2213-2600(18)30339-4. Epub 2018 Sep 14.
5
Successful Concomitant Therapy with Pirfenidone and Nintedanib in Idiopathic Pulmonary Fibrosis: A Case Report.吡非尼酮与尼达尼布联合治疗特发性肺纤维化成功：一例报告
Respiration. 2016;91(4):327-32. doi: 10.1159/000444690. Epub 2016 Apr 14.
6
Nintedanib for idiopathic pulmonary fibrosis in the Japanese population.尼达尼布用于日本人群特发性肺纤维化的治疗。
Respirology. 2017 May;22(4):630-631. doi: 10.1111/resp.13033. Epub 2017 Apr 3.
7
Nintedanib for idiopathic pulmonary fibrosis: An Asian perspective.
Respirology. 2016 Nov;21(8):1342-1343. doi: 10.1111/resp.12903. Epub 2016 Sep 20.
8
Nintedanib: A Review of Its Use in Patients with Idiopathic Pulmonary Fibrosis.尼达尼布：用于特发性肺纤维化患者的评价。
Drugs. 2015 Jul;75(10):1131-40. doi: 10.1007/s40265-015-0418-6.
9
Nintedanib for the treatment of idiopathic pulmonary fibrosis.尼达尼布用于治疗特发性肺纤维化。
Expert Opin Pharmacother. 2018 Feb;19(2):167-175. doi: 10.1080/14656566.2018.1425681. Epub 2018 Jan 12.
10
Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension.尼达尼布治疗特发性肺纤维化患者的长期疗效：来自 TOMORROW 试验及其开放标签扩展研究的结果。
Thorax. 2018 Jun;73(6):581-583. doi: 10.1136/thoraxjnl-2016-209701. Epub 2017 Oct 9.

本文引用的文献

1
Pirfenidone: A novel hypothetical treatment for COVID-19.吡非尼酮：一种针对新型冠状病毒肺炎的新型假设性治疗方法。
Med Hypotheses. 2020 Nov;144:110005. doi: 10.1016/j.mehy.2020.110005. Epub 2020 Jun 17.
2
Nintedanib in advanced NSCLC: management of adverse events.尼达尼布治疗晚期非小细胞肺癌：不良事件的管理
Lung Cancer Manag. 2016 Apr;5(1):29-41. doi: 10.2217/lmt.15.33. Epub 2015 Nov 3.
3
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.尼达尼布治疗特发性肺纤维化的疗效和安全性。
N Engl J Med. 2014 May 29;370(22):2071-82. doi: 10.1056/NEJMoa1402584. Epub 2014 May 18.
4
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).吲哚啉酮类作为三重血管激酶抑制剂的设计、合成与评估以及一种高度特异性的6-甲氧基羰基取代吲哚啉酮（BIBF 1120）的发现
J Med Chem. 2009 Jul 23;52(14):4466-80. doi: 10.1021/jm900431g.
5
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.BIBF 1120：具有持续受体阻断作用和良好抗肿瘤疗效的三联血管激酶抑制剂。
Cancer Res. 2008 Jun 15;68(12):4774-82. doi: 10.1158/0008-5472.CAN-07-6307.